Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

Inclusion Criteria: * Children and adults regardless of age or weight allograft for primary or secondary acute leukemia, MDS, lympho-proliferative syndrome (CLL, Myeloma, Lymphoma) or myelo-proliferative syndrome. * Prior allogeneic HSCT (myeloablative or non-myeloablative conditioning) from a family donor geno-identical HLA or a volunteer donor HLA 10/10 or 9/10. * Molecular, cytogenetic, cytological relapse regardless of the date after the transplant. * Previous standard DLI should have brought a total dose of at least 5.10\^6 CD3 + / kg (donor HLA-geno idendique) or 2.10\^6 CD3 + / kg (voluntary donor) or 5.10\^5 CD3+/kg (donor haplo-idendique). * Patient corresponding to the failure criteria of a previous standard DLI, defined for each type of hematological malignancies in the test model "DLI-Treg-1" after a delay of at least 30 days in the case of a progressive disease after DLI and at least 60 days in the case of stable disease (due to possible delayed responses after DLI). * Patient consented to the study (the consent of both parents will be collected for minors) * Patients insured by a social security system. * Negative pregnancy test (β-HCG hormone) within the 7 days prior to enrollment Exclusion Criteria: * Presence of acute GVHD grade\> II or extensive chronic GVHD since the first DLI * Patient receiving immunosuppressive therapy for the treatment of GVHD or other reason * Impairment of liver function (transaminases\> 5 N or bilirubin\> 50 µM except Gilbert's disease) or renal function (creatinine clearance \<30 ml / min) * OMS performance status \> 2 * Non controlled severe infection * Patient under tutorship, curatorship or legal protection Donor Inclusion Criteria * Being the initial HSC donor (HLA geno-identical family or haplo-identique or non-family HLA 10/10 or 9/10) * Weight ≥20 kg authorizing the lymphapheresis * Having no contra-indications for donating blood * Absence of severe heart failure, unstable heart disease, uncontrolled hypertension, type 1 diabetes * Negative serology for HIV1-2, HBV, HCV, HTLV 1 and VDRL/TPHA in the 30 days prior to apheresis. Negative viral genomics diagnosis is required for HIV, HBV and HCV * Being informed of the study, and have given an oral non opposition